BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2427298)

  • 1. Synthesis and retention of methotrexate polyglutamates in Ehrlich ascites carcinoma cells.
    Balińska M
    Drugs Exp Clin Res; 1986; 12(6-7):551-4. PubMed ID: 2427298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of methotrexate polyglutaminate formation in Ehrlich ascites carcinoma cells by endogenous folate pool.
    Balińska M
    Acta Biochim Pol; 1986; 33(1):31-7. PubMed ID: 2424199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of the intracellular levels of polyglutamyl derivatives of methotrexate by vincristine and probenecid in Ehrlich ascites tumor cells.
    Fry DW; Yalowich JC; Goldman ID
    Cancer Res; 1982 Jul; 42(7):2532-6. PubMed ID: 6177396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitro.
    Matherly LH; Voss MK; Anderson LA; Fry DW; Goldman ID
    Cancer Res; 1985 Mar; 45(3):1073-8. PubMed ID: 2578870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of the accumulation of methotrexate polyglutamate derivatives in Ehrlich ascites tumor cells and isolated rat hepatocytes.
    Fry DW; Gewirtz DA; Yalowich JC; Goldman ID
    Adv Exp Med Biol; 1983; 163():215-34. PubMed ID: 6193686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.
    Pizzorno G; Mini E; Coronnello M; McGuire JJ; Moroson BA; Cashmore AR; Dreyer RN; Lin JT; Mazzei T; Periti P
    Cancer Res; 1988 Apr; 48(8):2149-55. PubMed ID: 2450647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro.
    Yalowich JC; Fry DW; Goldman ID
    Cancer Res; 1982 Sep; 42(9):3648-53. PubMed ID: 6179605
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of methotrexate polyglutamates in methotrexate- and sequential methotrexate-5-fluorouracil-mediated cell kill.
    McGuire JJ; Mini E; Hsieh P; Bertino JR
    Cancer Res; 1985 Dec; 45(12 Pt 1):6395-400. PubMed ID: 2415244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the in vivo synthesis of methotrexate polyglutamates and their efflux properties in normal, proliferative, and neoplastic mouse tissues.
    Poser RG; Sirotnak FM
    Adv Exp Med Biol; 1983; 163():259-74. PubMed ID: 6193689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo.
    Poser RG; Sirotnak FM; Chello PL
    Cancer Res; 1981 Nov; 41(11 Pt 1):4441-6. PubMed ID: 6171339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ methotrexate polyglutamate formation in rat tissues.
    Krakower GR; Kamen BA
    J Pharmacol Exp Ther; 1983 Dec; 227(3):633-8. PubMed ID: 6197519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsic resistance of cervical squamous cell carcinoma cell lines to methotrexate (MTX) as a result of decreased accumulation of intracellular MTX polyglutamates.
    Barakat RR; Li WW; Lovelace C; Bertino JR
    Gynecol Oncol; 1993 Oct; 51(1):54-60. PubMed ID: 7694891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.
    Koizumi S; Curt GA; Fine RL; Griffin JD; Chabner BA
    J Clin Invest; 1985 Mar; 75(3):1008-14. PubMed ID: 2579975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of methotrexate polyglutamates in rat hepatocytes.
    Gewirtz DA; White JC; Randolph JK; Goldman ID
    Cancer Res; 1979 Aug; 39(8):2914-8. PubMed ID: 455278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug.
    Pizzorno G; Chang YM; McGuire JJ; Bertino JR
    Cancer Res; 1989 Oct; 49(19):5275-80. PubMed ID: 2475246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
    Jolivet J; Chabner BA
    J Clin Invest; 1983 Sep; 72(3):773-8. PubMed ID: 6193143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of methotrexate cytotoxicity by asparaginase inhibition of methotrexate polyglutamate formation.
    Jolivet J; Cole DE; Holcenberg JS; Poplack DG
    Cancer Res; 1985 Jan; 45(1):217-20. PubMed ID: 2578094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity.
    Fry DW; Anderson LA; Borst M; Goldman ID
    Cancer Res; 1983 Mar; 43(3):1087-92. PubMed ID: 6186369
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of polyglutamates in methotrexate action.
    Wilmanns W; Schalhorn A
    Chemioterapia; 1985 Oct; 4(5):349-53. PubMed ID: 2416481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y.
    Sur P; Fernandes DJ; Kute TE; Capizzi RL
    Cancer Res; 1987 Mar; 47(5):1313-8. PubMed ID: 2434214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.